Last updated: 2026-09-08 05:30:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
AC Immune SA (ACIU) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2.86, with a market capitalisation of $284.36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.10 to $4.00. This page covers its latest market performance, valuation, price trends and company information.
$284.36M | |
$2.91 | |
$19.97 | |
$1.43 | |
$2.93 | |
151.71K | |
245.19K | |
-- | |
$4.00 | |
$2.10 | |
-- | |
-- |
AC Immune SA (ACIU) last closed at $2.93 as of 2026-09-04 23:59:00, unchanged from the previous close of $2.93.
During the latest regular trading session, ACIU traded between $1.43 and $19.97, with a volume of 151.71K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, AC Immune SA (ACIU) moved from $2.71 to $2.86, representing a gain of 5.39% ($0.15).
The stock traded between $2.58 and $3.00 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 156.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 39.9%
ACIU is currently trading at $2.86, placing it 39.9% of the way from its 52-week low of $2.10 to its 52-week high of $4.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
| Employees | 122 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AC Immune SA (ACIU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.